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154 Poster Session-IIsubcutaneous group.We conclude that subcutaneous administration
of alemtuzumab shows similar outcomes as intravenous administra-
tion in the reduced intensity preparatory regime for non-malignant
diseases with less toxicity to the patient.438
USE OF A CALCIUM/PHOSPHATE ORAL RINSE (CAPHOSOLR) TO LESSEN
THE MUCOSITIS FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION
Bechtel, T.P.1, Devine, S.2 1Arthur G James Cancer Hospital and Richard
J Solove Research Institute at the Ohio State University Medical Center,
Columbus, OH; 2Arthur G James Cancer Hospital and Richard J Solove
Research Institute at the Ohio State UniversityMedical Center, Columbus,
OH
The high-dose chemotherapy/radiation therapy employed in the
conditioning regimens prior to hematopoietic stem cell transplanta-
tion have a considerable negative effect on the oral epithelium. De-
pending on the agents and doses administered, oral mucositis can
range from mild to life threatening. The consequences of this
mucositis, depending on its degree, can impact a patients ability to
maintain oral hydration, nutrition and intake of medications. Addi-
tionally, the potential for local and systemic infections increases dra-
matically with the loss of the natural mucosal barrier. Many
interventions have been tried over the years to lessen the degree of
mucositis and all have met with mixed, inconsistent results. The re-
cent introduction of a new agent, CaphosolR, has added to the list of
potential treatments. One conditioning protocol that has consis-
tently produced varying degrees of mucositis in our patients is the
BEAM regimen. It consists of carmustine, etoposide, cytarabine
and melphalan given intravenously over a 6 day period and is widely
used in the non-Hodgkins lymphoma population. Previous attempts
to modify the mucositis have been met with marginal success so it
was decided to trial CaphosolR in this setting. CaphosolR was pre-
pared according to the manufacturers instructions and administered
4 times daily to 9 patients receiving the BEAM regimen. This group
was compared to 13 patients that received BEAM in the previous 6
months who did not get CaphosolR. Some degree of mucositis was
seen in all the patients which required narcotic analgesic interven-
tion. Themost severe cases required the use of patient controlled an-
algesia (PCA) with either morphine or hydromorphone. We found
that four (4) patients in each group needed PCA however the Capho-
solR group needed a mean of only 4.25 days of PCA therapy vs 5.5
days in the other group and the overall patient pain rating was less
in the CaphosolR population. We also found that the length of
stay after transplantation (LOS) was 1.5 days less in the CaphosolR
group (14.5 vs 15.9 days) while the mean number of days on Capho-
solR was 10.2. It was felt that the treatment had a positive effect on
patient outcome and quality of life and it is now used in all patients
receiving BEAM therapy. We continue to evaluate it in this group
along with other transplant populations, non-transplant chemother-
apy patients and those receiving radiotherapy for head/neck cancer.439
ATTENUATED KERATINOCYTE GROWTH FACTOR AND ETOPOSIDE
BASED CONDITIONING FOR ALLOGENEIC TRANSPLANT
Booth, D.L. Royal Melbourne Hospital, Melbourne, Victoria, Australia
Objective:Assess the impact of keratinocyte growth factor (KGF)
administered prior to conditioning only, on oral mucositis in alloge-
neic transplant recipients receiving etoposide based conditioning.
Method: All patients scheduled for HSCT with TBI/ Etoposide
or Bu/Cy/Etoposide from June 2006 to August 2008 were offered
KGF at 60 mcg/kg on 3 consecutive days finishing 24 hours prior
to conditioning. Work previously done in our institution showed
KGF was not beneficial in allogeneic patients receiving myeloabla-
tive conditioning regimens. This result was attributed to scheduling
of post conditioning KGF and short course methotrexate despite
omission of day11 KGF to avoid coadministration within 24 hours.
Therefore, in this cohort of patients post conditioning KGF doses
were omitted completely. WHO oral mucositis score, duration,
TPN and analgesia usage were recorded prospectively.
Results: Twelve patients (8 allogeneic, 4 MUDs, 7 B-ALL, 2
Ph1ve ALL, 2 T-ALL, 1 biphenotypic leukaemia) consented toKGF. Conditioning was TBI/etoposide in 10 patients TBI/thymo-
globulin/etoposide in 1 patient and Bu/Cy/etoposide in 1 patient
with CSA and MTX on days 1, 3, 6 and 11 as GVHD prophylaxis.
Grade 3 to 4 mucositis was experienced by 8/12 patients (67%) com-
pared to 36/38 (95%) of TBI etoposide patients prior to June 2006
(P 5 0.024). Mean duration of TPN was 13.5 days compared to
18 days and mean duration of opiate analgesia was 11.5 days
compared 14.5 days for KGF cohort and the historical cohort
respectively.
Conclusions: Attenuated KGF is effective for amelioration of
oral mucositis associated with etoposide containing conditioning
in allogeneic transplants.440
A RAPID NANOPARTICLE IMMUNOASSAY TO QUANTITATE BUSULFAN IN
PLASMA
Salamone, S.J.1, Benfield, C.N.1, Courtney, J.B.1, Harney, R.L.1,
Kozo, D.R.1, Li, Y.1, Lundell, G.D.1, Shaw, L.M.2, Gardiner, J.A.M.2
1Saladax Biomedical Inc, Bethlehem, PA; 2University of Pennsylvania
Medical Center, Philadelphia, PA
Background: Busulfan (BU), a bifunctional alkylating agent, is
the most widely used chemotherapeutic agent as a component of
high-dose conditioning regimens for hematopoietic stem cell trans-
plantation (HSCT). Studies have shown that maintaining a targeted
exposure [expressed as area under the time-curve (AUC)] throughout
the complete regimen is essential for successful engraftment,
reduced risk of graft vs. host disease or venoocclusive disease. For
optimal therapeutic drug management (TDM), an assay that can
deliver rapid high quality results would be desirable.
Methods: Monoclonal antibodies bound to nanoparticles were
used to develop an immunoassay for the Roche c111 chemistry
analyzer. The assay was monitored at 629 nm and quantitated with
a stabilized calibrator of busulfan. Assay precision, linearity, calibra-
tion stability and limit of detection (LoD) were determined. Clinical
samples were analyzed and correlated with GC-MS.
Results:With six calibrators from0–2,000 ng/mL, a stabilized bu-
sulfan derivative, and auto-dilution, plasma samples with concentra-
tions up to 10,000 ng/mL could be determined. Time-to-first-result
was 12 min and 25 samples/h could be measured from a stored stan-
dard curve. Imprecision across the range of assay was\7% and the
assaywas linear upondilutionover the entire range.Cross-reactivities
for sulfolane, tetrathiophene and 3-hydroxsulfolane were\1%. The
LoDwas 50 ng/mLwith a functional sensitivity of 100 ng/mL. Assay
results of clinical samples (237 to 1,711ng/mL) correlated well with
GC-MS results: (R. 0.98, slope 1.05, intercept5 39 ng/mL).
Conclusions: This immunoassay is suitable for determining bu-
sulfan concentrations in plasma. It offers advantages of turn-around
time, small sample size, no sample pre-treatment and a stable calibra-
tor that can be stored at room temperature. Automation and rapid
turn-around time with a small benchtop analyzer enable efficient
routine monitoring of busulfan concentrations in clinical practice
which can lead to better patient care.441
PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL
BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA
(AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
Hutcherson, D.A.1, Surati, M.1, Sanvidge, K.1, Harvey, D.2, Al-
Baldawi, R.N.3, Langston, A.2, Flowers, C.2, Lonial, S.2, Kaufman, J.2,
Lechowicz, M.J.2, Waller, E.2 1Emory Healthcare, Atlanta, GA; 2Emory
University, Atlanta, GA; 3Mercer University, Atlanta, GA
Background: Busulfan (Bu) and cyclophosphamide are widely
used in conditioning regimens before hematopoietic cell transplan-
tation. Increased relapse rates and graft rejection have previously
been reported with low Bu area-under-the-curve (AUC) micromol*
min/L, and sinusoidal obstruction syndrome is associated with high
AUCs.This has lead to strategies to adjust Bu dosing to achieve a tar-
get AUC. Previous studies have suggested that a 0.8 mg/kg dose of
IV Bu would achieve an AUC similar to that of 1 mg/kg of oral
Bu. PK monitoring of IV Bu at our institution demonstrated that
